These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14990642)

  • 21. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
    Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
    Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice.
    Gutman M; Couillard S; Roy J; Labrie F; Candas B; Labrie C
    Int J Cancer; 2002 May; 99(2):273-8. PubMed ID: 11979444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.
    Buzdar A; O'Shaughnessy JA; Booser DJ; Pippen JE; Jones SE; Munster PN; Peterson P; Melemed AS; Winer E; Hudis C
    J Clin Oncol; 2003 Mar; 21(6):1007-14. PubMed ID: 12637464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pure antiestrogens and breast cancer.
    Elkak AE; Mokbel K
    Curr Med Res Opin; 2001; 17(4):282-9. PubMed ID: 11922402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients.
    Alliot C
    J Clin Oncol; 2005 Jun; 23(18):4237-8; author reply 4238-9. PubMed ID: 15961776
    [No Abstract]   [Full Text] [Related]  

  • 27. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.
    Hird RB; Chang A; Cimmino V; Diehl K; Sabel M; Kleer C; Helvie M; Schott A; Young J; Hayes D; Newman L
    Cancer; 2006 May; 106(10):2113-8. PubMed ID: 16596655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptors as therapeutic targets in breast cancer.
    Ariazi EA; Ariazi JL; Cordera F; Jordan VC
    Curr Top Med Chem; 2006; 6(3):181-202. PubMed ID: 16515478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group.
    Delozier T; Spielmann M; Macé-Lesec'h J; Janvier M; Hill C; Asselain B; Julien JP; Weber B; Mauriac L; Petit JC; Kerbrat P; Malhaire JP; Vennin P; Leduc B; Namer M
    J Clin Oncol; 2000 Oct; 18(20):3507-12. PubMed ID: 11032592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
    Simard J; Sanchez R; Poirier D; Gauthier S; Singh SM; Merand Y; Belanger A; Labrie C; Labrie F
    Cancer Res; 1997 Aug; 57(16):3494-7. PubMed ID: 9270018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
    Zhou Y; Yau C; Gray JW; Chew K; Dairkee SH; Moore DH; Eppenberger U; Eppenberger-Castori S; Benz CC
    BMC Cancer; 2007 Apr; 7():59. PubMed ID: 17407600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer.
    Goss PE; Strasser K; Marques R; Clemons M; Oza A; Goel R; Blackstein M; Kaizer L; Sterns EE; Nabholtz JM; De Coster R; Crump M; Abdolell M; Qi S
    Breast Cancer Res Treat; 2000 Nov; 64(2):177-88. PubMed ID: 11194453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
    Safra T; Greenberg J; Ron IG; Ben-Yosef R; Inbar M; Sarid D; Yaal-Hahoshen N
    Isr Med Assoc J; 2008 May; 10(5):339-43. PubMed ID: 18605354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK
    Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.
    Munster PN; Thurn KT; Thomas S; Raha P; Lacevic M; Miller A; Melisko M; Ismail-Khan R; Rugo H; Moasser M; Minton SE
    Br J Cancer; 2011 Jun; 104(12):1828-35. PubMed ID: 21559012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of droloxifene in patients with metastatic breast cancer.
    Buzdar AU; Kau S; Hortobagyi GN; Theriault RL; Booser D; Holmes FA; Walters R; Krakoff IH
    Cancer Chemother Pharmacol; 1994; 33(4):313-6. PubMed ID: 8281625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
    van Hezewijk M; Bastiaannet E; Putter H; Scholten AN; Liefers GJ; Rea D; Hasenburg A; Paridaens R; Hozumi Y; Markopoulos C; Seynaeve C; Jones SE; Marijnen CA; van de Velde CJ
    Radiother Oncol; 2013 Aug; 108(2):190-6. PubMed ID: 24044798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.